Interim results: XF-73 3 – 0 The competition
There were few surprises in Destiny Pharma’s interim results as the recent achievements on its two...
Read moreRecovery slow, new strategy in place
After early signs of green shoots during Q2, what is clear is that customers are mindful of...
Read moreDouble digit ARR growth
Corero’s cyber defence solutions delivered double digit growth in order intake, revenue and ARR in...
Read more
Results in-line; Prioritising cash generation in FY24
Springfield’s results to May ’23 are in line with expectations, confirming a record year of...
Read more
Western growth enhanced by Eastern promise
The Artisanal Spirits Company (ASC)’s FY2023 H1 results reconfirmed a strong Q2 as well as showing...
Read moreRising margins and NAV bode well
The recent results for the six months to June reflected the positive contributions from the HIOS...
Read moreSolid FY23, with acquisition synergies realised
Client assets closed FY23 (to 31 May 23) on £15.3bn, up £0.4bn (3%) y-o-y (31 May 22: £14.9bn)....
Read moreRevenue & profit beat forecast but outlook cautious
FUM closed FY23 (30 Jun 23) on £16.8bn, 7.5% up y-o-y (30 Jun 22: £15.7bn). This was the ...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
